Status:
UNKNOWN
Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
University of Coimbra
Conditions:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Validation of the exendin-based beta cell imaging technique in patients with type 2 diabetes
Detailed Description
Rationale: Reliable imaging biomarkers for non-invasive characterisation of beta-cell mass (BCM) are needed to aid understanding regarding the relationship between beta-cell mass and function during t...
Eligibility Criteria
Inclusion
- Scheduled for partial or complete pancreatectomy at Radboudumc
Exclusion
- Previous treatment with synthetic exendin or dipeptidyl-peptidase IV inhibitors within the past 3 months
- Breast feeding
- Pregnancy or the wist to become pregnant within 6 months
- Creatinine clearance below 40ml/min
- Liver disease defined as aspartate aminotransferase of alanine aminotransferase level of more than three times the upper limit of normal range
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04733508
Start Date
November 1 2019
End Date
December 1 2022
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands, 6525 GA